Many women ignore early breast changes, hoping they will disappear on their own. Delaying medical attention, however, can allow breast cancer to progress and spread. Invasive ductal carcinoma (IDC) is one of the most common types of breast cancer, affecting a large number of women worldwide. With early diagnosis and the right invasive carcinoma treatment, many patients can achieve positive treatment results. At the CK Birla Hospital, our breast cancer specialists provide comprehensive care for patients diagnosed with this condition, helping them understand their options and make informed treatment decisions.
Invasive ductal carcinoma is the most common type of breast cancer. It begins in the milk ducts of the breast and then spreads into the surrounding breast tissue. Because it has moved beyond the ducts, it is referred to as ‘invasive.’
If it is left untreated, invasive ductal carcinoma can spread to the nearby lymph nodes and other parts of the body. However, many cases are diagnosed before major spread happens, allowing effective treatment. IDC can affect women of all ages, though it is more commonly diagnosed after the age of 50. In rare cases, it can also affect men.
Invasive ductal carcinoma can vary based on its microscopic appearance and behaviour.
In this stage, cancer cells look somewhat similar to normal breast cells and tend to grow slowly.
Invasive ductal carcinoma grade 2 treatment is commonly required when cancer cells show moderate abnormalities and a moderate growth rate. Treatment may include surgery, radiation therapy, chemotherapy, hormone therapy or targeted therapy depending on the tumour characteristics.
Cancer cells appear significantly different from normal cells and may grow more aggressively.
These cancers grow in response to hormones such as estrogen or progesterone and often respond well to hormone therapy.
This subtype has increased HER2 protein expression and may benefit from targeted medications.
This form lacks hormone receptors and HER2 expression, requiring chemotherapy as a major treatment approach.
There are many factors that can increase the risk of developing breast cancer.
Some common risk factors are:
Having one or more risk factors does not necessarily mean a person will develop breast cancer. Likewise, some patients diagnosed with IDC may have no identifiable risk factors.
Symptoms may vary from person to person. Some patients experience changes during self-examination, while others are diagnosed through routine mammography.
Common signs of IDC are:
Any persistent breast change should be evaluated by a breast specialist without delay
The choice of invasive carcinoma treatment depends on various factors, including tumour size, cancer stage, grade, lymph node involvement, hormone receptor status, HER2 status and overall health of the patient.
Surgery: It is generally the primary treatment for invasive ductal carcinoma.
Lumpectomy: It is also called breast conserving surgery. This procedure removes the tumor along with a margin of healthy tissue while preserving most of the breast.
Radiation Therapy: Radiation therapy uses high energy beams to destroy remaining cancer cells after surgery. It is commonly recommended after lumpectomy and in selected cases after mastectomy.
Chemotherapy: Chemotherapy uses anti-cancer drugs to destroy cancer cells throughout the body. It may be administered before surgery to shrink the tumor or after surgery to reduce recurrence risk.
Hormone Therapy: For hormone receptor-positive cancers, hormone therapy helps block the effects of estrogen that can promote tumor growth.
Targeted Therapy: Targeted treatments focus on specific cancer-related proteins such as HER2. These therapies can improve outcomes for eligible patients while minimising damage to healthy tissues.
Personalised Treatment Planning: A multidisciplinary team approach helps create an individualised treatment strategy designed around the patient’s specific diagnosis and goals.
Recovery varies depending on the type of surgery and additional treatments required.
Patients can generally expect:
Most patients can resume many routine activities within a few weeks, although recovery timelines differ from person to person.
Emotional recovery is equally important. Support from healthcare professionals, family members, and support groups can help patients navigate treatment and recovery more confidently.
The CK Birla Hospital offers an integrated approach to breast cancer care, with a focus on accurate diagnosis and personalised treatment planning. Our dedicated ‘Breast Centre’ brings together specialists across disciplines to provide coordinated care and support throughout the treatment journey.
If you have been diagnosed with invasive ductal carcinoma or are experiencing concerning symptoms, schedule a consultation with the breast cancer specialists to discuss diagnosis and treatment options.
Yes. invasive ductal carcinoma is a form of breast cancer that requires medical treatment. The seriousness depends on factors such as stage, tumour size, grade and whether the cancer has spread. Early diagnosis leads to better treatment results.
Ductal carcinoma in situ (DCIS) remains confined within the milk ducts and has not spread into surrounding tissue. Invasive ductal carcinoma has broken through the duct walls and entered nearby breast tissue.
The need for chemotherapy depends on tumour characteristics, stage, lymph node involvement, hormone receptor status, and HER2 status. Some patients may be treated with surgery, radiation therapy, hormone therapy, or targeted therapy without chemotherapy.
Many patients with early stage invasive ductal carcinoma achieve successful treatment outcomes. Prognosis depends on factors such as cancer stage, grade, biological characteristics and response to treatment. Early diagnosis and timely treatment remain important factors in improving outcomes.
